Radiopharm Theranostics Secures A$5.88 Million Refund from Australian R&D Tax Incentive for FY2025

Key Points<\/h3>

• Company: Radiopharm Theranostics Limited (ASX: RAD, Nasdaq: RADX)<\/li>
• Received an Australian Government R&D tax refund of A$5,885,131 for FY2025, inclusive of A$104,475 interest<\/li>
• Refund granted under the Australian Government's R&D Tax Incentive program, which provides a refundable tax offset of up to 43.5% for qualifying activities<\/li>
• Funds intended to support ongoing development of Radiopharm's radiopharmaceutical product portfolio<\/li>
• Investors should monitor updates on the company’s clinical program, which includes one Phase 2 and five Phase 1 trials targeting multiple solid tumour cancers<\/li> <\/ul> <\/div>

  Details of Radiopharm's A$5.88 Million R&D Tax Refund Including Interest<\/h2>

  On 3 July 2026, Radiopharm Theranostics confirmed it received its research and development tax refund for the 2025 financial year, totaling A$5,885,131. This sum comprises the primary R&D tax offset and A$104,475 in accrued interest. The refund was processed under the Australian Government’s R&D Tax Incentive program.<\/p>

  The interest component reflects the Australian R&D Tax Incentive scheme’s structure, which allows eligible companies to obtain a cash refund rather than just a tax credit. This mechanism is particularly advantageous for clinical-stage companies like Radiopharm, which are not yet generating significant revenue. The refund provides a meaningful, non-dilutive source of working capital to support the company’s ongoing investment in its radiopharmaceutical pipeline.<\/p>

  Overview of the Australian Government's R&D Tax Incentive for Clinical-Stage Biotech Firms<\/h2>

  The Australian Government’s R&D Tax Incentive program encourages companies to conduct research and development activities that benefit the economy. Eligible companies with aggregated turnover under A$20 million can access a refundable tax offset of up to 43.5% on qualifying R&D expenditure. This refundable feature is especially beneficial for pre-revenue or early-revenue clinical-stage biotech companies, enabling them to receive cash refunds even when not liable for tax.<\/p>

  For Radiopharm, which runs multiple clinical trials across various cancer types, R&D costs are substantial. Recovering a significant portion of these expenses through the tax incentive extends the company’s operational runway without the need for additional equity or debt financing. Although Radiopharm did not specify how the funds will be allocated across its programs, the refund is expected to support continued product development.<\/p>

  Radiopharm's Diverse Radiopharmaceutical Pipeline Featuring Peptides, Small Molecules, and Monoclonal Antibodies<\/h2>

  Radiopharm Theranostics is a clinical-stage radiotherapeutics company with an innovative platform of radiopharmaceutical products for diagnostic and therapeutic use. Its pipeline includes three technology platforms: peptides, small molecules, and monoclonal antibodies, each targeting cancers with high unmet medical needs.<\/p>

  This multi-platform approach offers diversification across cancer biology targets and delivery methods. Radiopharmaceuticals combine targeting molecules with radioactive payloads, enabling precise radiation delivery directly to tumour cells. Radiopharm’s focus places it within a rapidly evolving segment of oncology drug development.<\/p>

  Active Clinical Trials: One Phase 2 and Five Phase 1 Studies Targeting Solid Tumour Cancers<\/h2>

  According to the company update, Radiopharm has an active clinical program consisting of one Phase 2 trial and five Phase 1 trials. These studies cover various solid tumour cancers, including lung, breast, and brain cancers. This extensive clinical activity highlights the company’s significant investment in development and underscores the importance of the R&D tax refund as a funding source.<\/p>

  Phase 1 trials primarily assess safety, tolerability, and dosing, while Phase 2 trials evaluate efficacy in larger patient groups. The presence of both phases indicates that at least one program has progressed beyond initial safety assessments. Investors may look for upcoming clinical data as key catalysts.<\/p>

  Significance of Non-Dilutive Funding and Impact on Radiopharm's Cash Position<\/h2>

  For clinical-stage biotech companies, managing cash runway is crucial. R&D tax refunds provide non-dilutive capital, meaning no new shares or debt issuance is required. The A$5,885,131 refund thus strengthens Radiopharm’s financial position without diluting shareholders.<\/p>

  The company stated the refund will fund ongoing development of its radiopharmaceutical portfolio. While no specific allocation was disclosed, this capital infusion is likely to support operational costs for multiple concurrent trials. No updated cash balance or runway guidance was provided in this announcement.<\/p>

  Radiopharm’s Dual Listing on ASX and Nasdaq Enhances Investor Access<\/h2>

  Radiopharm Theranostics is dual-listed on the Australian Securities Exchange (ASX:RAD) and Nasdaq (RADX). This structure provides access to both Australian and U.S. investors, important in the radiopharmaceutical sector, which has attracted global institutional interest following notable commercial successes in theranostics.<\/p>

  The dual listing ensures corporate updates, including this R&D tax refund announcement, reach both markets simultaneously. For U.S. investors, the refund highlights the scale of Radiopharm’s Australian R&D expenditure and engagement with local funding frameworks. The announcement was authorized by Executive Chairman Paul Hopper.<\/p>

  Focus on Oncology Indications with High Unmet Medical Needs<\/h2>

  Radiopharm’s mission is to develop radiopharmaceuticals targeting oncology indications with significant unmet needs. Its clinical programs include lung, breast, and brain cancers—some of the most prevalent and challenging cancer types globally. Lung cancer remains a leading cause of cancer mortality, while brain cancers such as glioblastoma have poor prognoses.<\/p>

  The radiopharmaceutical approach delivers targeted radiation via cancer-seeking molecules, potentially offering more precise treatment with less systemic toxicity than conventional radiotherapy. Radiopharm’s multiple candidates in Phase 1 and 2 trials indicate ongoing progress in scientific and clinical development.<\/p>

  Board Authorization and Leadership Behind the FY2025 R&D Tax Refund Announcement<\/h2>

  The update was authorized by Executive Chairman Paul Hopper on behalf of Radiopharm’s Board of Directors. Hopper is actively involved in strategic direction and can be contacted through the company’s disclosed details. CEO and Managing Director Riccardo Canevari, based in the U.S., serves as the primary investor relations contact.<\/p>

  Investor relations support is provided externally by Precision AQ (formerly Stern IR), with Anne Marie Fields as the contact. Media inquiries are handled by Matt Wright of NWR Communications. This dedicated IR and communications support reflects the company’s dual-listed status and the need for consistent engagement across markets. No management quotes were included regarding the refund.<\/p>

  Investor Outlook Following Receipt of the R&D Tax Incentive Refund<\/h2>

  With the refund secured, investors will likely focus on how Radiopharm deploys this capital across its clinical programs. Key upcoming milestones include updates from the Phase 2 and Phase 1 trials, as clinical data readouts are expected to be significant value drivers. No timeline for these updates was provided.<\/p>

  The successful refund confirms Radiopharm’s R&D activities were deemed eligible under the Australian Government’s incentive framework, validating its R&D processes and documentation. Sustaining access to government-backed funding like the R&D Tax Incentive is critical for the company’s funding strategy alongside equity and capital market activities. The immediate effect on share price was not evident from public information.<\/p>